Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Rslcan-11 Inhibitors

Rslcan-11 inhibitors represent a distinct class of chemical compounds that function by specifically targeting and modulating the activity of the Rslcan-11 protein. The Rslcan-11 protein is part of a broader family of regulatory proteins involved in critical biochemical pathways, such as cell signaling and metabolic regulation. These proteins often act as molecular switches, controlling various processes within cells by interacting with other proteins or cellular components. Inhibitors of Rslcan-11 are designed to bind to active sites on the Rslcan-11 protein, effectively hindering its ability to participate in or catalyze its associated reactions. The molecular architecture of these inhibitors is typically characterized by a high degree of specificity, often involving aromatic rings, nitrogenous bases, or hydrophobic domains that engage in precise interactions with the active site of Rslcan-11.

Structurally, Rslcan-11 inhibitors can be categorized based on their mechanism of action, such as competitive or allosteric inhibition. Competitive inhibitors often resemble the natural substrate of Rslcan-11, occupying the same binding site and preventing the substrate from interacting with the protein. Allosteric inhibitors, in contrast, bind to a different site on the protein, inducing conformational changes that reduce the protein's activity. Research into Rslcan-11 inhibitors also involves studying their physicochemical properties, such as solubility, stability, and binding affinity, which are crucial for understanding their interaction dynamics. These properties are often optimized to ensure that the inhibitor efficiently and selectively modulates the target protein, making Rslcan-11 inhibitors a topic of keen interest in chemical research focused on regulatory mechanisms within cellular systems.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$60.00
$265.00
$1000.00
163
(3)

Proteasome inhibitor that may stabilize transcription factors by preventing their degradation.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

DNA methyltransferase inhibitor, potentially affecting gene expression patterns including those of transcription factors.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

Histone deacetylase inhibitor, which can change chromatin structure and influence transcription factor accessibility.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

PI3K inhibitor that may affect numerous signaling pathways influencing transcription factor activity.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

p38 MAPK inhibitor, potentially affecting transcription factor regulation under stress conditions.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

JNK inhibitor, which may influence transcription factor activity in response to cellular stress.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

mTOR inhibitor, potentially affecting protein synthesis and stability, including that of transcription factors.

Nutlin-3

548472-68-0sc-45061
sc-45061A
sc-45061B
1 mg
5 mg
25 mg
$62.00
$225.00
$779.00
24
(1)

MDM2 antagonist, potentially stabilizing p53 and affecting its downstream transcriptional targets.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$111.00
$357.00
8
(0)

Modulates the ubiquitin-proteasome system, indirectly influencing transcription factor levels.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

BRAF inhibitor, potentially affecting transcription factors through the MAPK pathway.